E2F-1 [p Ser364] Antibody NB600-900 from Novus Biologicals, a Bio-Techne Brand

Supplier Images

E2F-1 [p Ser364] Antibody

Western Blot: E2F-1 [p Ser364] Antibody [NB600-900] - Panel A: Control antibody reactive to all forms of E2F (arrowheads). Panel B: Reactivity with phosphorylated E2F-1 (arrows) using E2F-1 [p Ser364] antibody. Lysate cells: CRE/E2F-1 CRE (human E2F-1 transfected mouse NIH3T3); NIH-3T3 (-ve control), & MDA-MB-231. Each lysate prepared from untreated cells & cells with 2 uM Doxorubicin. MDA-MB-231 also treated with genistein. Same membrane probed with E2F-1 [p Ser364] antibody @ 1:250 dilution, then stripped & re-probed with pan E2F antibody (+ve control). +ve control antibody shows an E2F-1 band in all human cell lines, but not mouse cells. Doxorubicin increases expression of E2F-1 (Panel A). Images overlapped to confirm that specific anti-E2F-1 pS364 staining shown in treated human cells in Panel B specifically aligns with E2F-1 staining shown in Panel A. Blots can be processed with HRP conjugated Gt-a-Rabbit IgG MX10 for 45 min at RT for ECL detection.
E2F-1 [p Ser364] Antibody

E2F-1 [p Ser364] Antibody
E2F-1 [p Ser364] Antibody

Western Blot: E2F-1 [p Ser364] Antibody [NB600-900] - Panel A: Control antibody reactive to all forms of E2F (arrowheads). Panel B: Reactivity with phosphorylated E2F-1 (arrows) using E2F-1 [p Ser364] antibody. Lysate cells: CRE/E2F-1 CRE (human E2F-1 transfected mouse NIH3T3); NIH-3T3 (-ve control), & MDA-MB-231. Each lysate prepared from untreated cells & cells with 2 uM Doxorubicin. MDA-MB-231 also treated with genistein. Same membrane probed with E2F-1 [p Ser364] antibody @ 1:250 dilution, then stripped & re-probed with pan E2F antibody (+ve control). +ve control antibody shows an E2F-1 band in all human cell lines, but not mouse cells. Doxorubicin increases expression of E2F-1 (Panel A). Images overlapped to confirm that specific anti-E2F-1 pS364 staining shown in treated human cells in Panel B specifically aligns with E2F-1 staining shown in Panel A. Blots can be processed with HRP conjugated Gt-a-Rabbit IgG MX10 for 45 min at RT for ECL detection.
E2F-1 [p Ser364] Antibody

Western Blot: E2F-1 [p Ser364] Antibody [NB600-900] - Panel A: Control antibody reactive to all forms of E2F (arrowheads). Panel B: Reactivity with phosphorylated E2F-1 (arrows) using E2F-1 [p Ser364] antibody. Lysate cells: CRE/E2F-1 CRE (human E2F-1 transfected mouse NIH3T3); NIH-3T3 (-ve control), & MDA-MB-231. Each lysate prepared from untreated cells & cells with 2 uM Doxorubicin. MDA-MB-231 also treated with genistein. Same membrane probed with E2F-1 [p Ser364] antibody @ 1:250 dilution, then stripped & re-probed with pan E2F antibody (+ve control). +ve control antibody shows an E2F-1 band in all human cell lines, but not mouse cells. Doxorubicin increases expression of E2F-1 (Panel A). Images overlapped to confirm that specific anti-E2F-1 pS364 staining shown in treated human cells in Panel B specifically aligns with E2F-1 staining shown in Panel A. Blots can be processed with HRP conjugated Gt-a-Rabbit IgG MX10 for 45 min at RT for ECL detection.